Table 1.

Select biomarker screening assays for the detection of epithelial ovarian cancer average specificity and sensitivity were calculated from studies with at least 250 subjects.

Test Name	Marker(s)	Modality	Potential Clinical Application(s)	Average Sens./Spec. (%)	Reference(s)
N/A	CA125	Protein	Preoperative diagnostic, Prognostic (FDA cleared)	83.7/86.0	[66,67,68]
ROMA®	CA125, HE4, and Menopause Status	Protein	Preoperative diagnostic, Prognostic (FDA cleared)	85.3/80.9	[68,69,70,71,72,73,74,75,76,77,78]
CPH-I	CA125, HE4, and Age	Protein	Preoperative diagnostic, Prognostic	82.2/78.9	[68,70,71,73,76,77,79]
OVA1®	CA125, ApoA-1, TTR, TF, and B2M	Protein	Preoperative diagnostic, Prognostic (FDA cleared)	87.7/52.6	[80,81,82,83,84,85]
Overa®	CA125, ApoA-1, TF, HE4, and FSH	Protein	Preoperative diagnostic, Prognostic (FDA cleared)	91.1/67.6	[86,87]
N/A	CA125, CA 15-3, CA72-4, and MCSF	Protein	Diagnostic	69.5/98.0	[88,89]
PapSEEK	ctDNA mutations	Genetic	Diagnostic, Prognostic	63.0/99.9	[90]
N/A	OPCML hypermethylation	Epigenetic	Screening, Diagnostic, and Prognostic	90.1/91.8	[91,92]
N/A	ZNF154 hypermethylation	Epigenetic	Diagnostic	67.6/93.5	[93,94,95]
CancerSEEK	ctDNA mutations and glycoproteins	Pan-cancer	Screening, Diagnostic, and Prognostic	96.0/99.0	[96]
N/A	miR-200(a/b/c) + miR-320 + miR-141, among others	MicroRNA	Diagnostic, Prognostic	85.3/96.0	[97,98,99,100,101]
N/A	VLDL, LDL, lysoPC, valine, alanine, and ceramides	Metabolite	Prognostic	78.9/93.2	[102,103,104,105]

CA125, cancer antigen 125; ApoA-1, apolipoprotein A1; TTR, transthyretin; TF, transferrin; B2M, beta-2-microglobulin; HE4, human epididymis protein 4; FSH, follicle stimulating hormone; CA72-4, cancer antigen 72-4; CA 15-3, cancer antigen 15-3; MCSF, macrophage colony stimulating factor; VLDL, very low-density lipids; LDL, low-density lipids; LysoPC, Lysophosphatidylcholines; ctDNA; circulating tumor DNA.